Business Context and Reporting Period
This Form 8-K filing by NanoViricides, Inc. covers the date of May 1, 2018. The report details the execution of a separation agreement with the company's former Chief Executive Officer and Director, Dr. Eugene Seymour, who resigned for personal reasons effective January 27, 2018.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data presented is limited to the specific terms of the executive separation agreement:
- Severance: Prorated monthly salary payments from January 27, 2018, through December 31, 2018.
- Cash Payment: $10,000 for up-front expenses.
- Equity Compensation: Warrants to purchase 250,000 shares of common stock at an exercise price of $2.00 per share.
Material Changes
The primary material change reported is the formalization of the departure of Dr. Eugene Seymour. While his resignation was previously disclosed in the Q4 2017 Form 10-Q, this filing confirms the entry into a binding Confidential Separation Agreement and General Release on May 1, 2018. Additionally, the company executed unregistered sales of equity securities (the warrants) under Section 4(2) and Rule 506 of Regulation D.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future business operations. The separation agreement includes standard risk-mitigating clauses for the company, including a general release of claims, and obligations of confidentiality, non-disclosure, and non-disparagement by the former executive.
Investor Verification Checklist
- Verify the exact amount of Dr. Seymour's monthly salary to calculate the total severance liability through December 31, 2018.
- Confirm the vesting schedule details for the 250,000 warrants (three equal installments over three years, ending May 1, 2021).
- Review the attached Exhibit 10.1 (Confidential Separation Agreement) for any additional non-financial covenants or conditions.
- Check subsequent filings to confirm the appointment of a new CEO or interim leadership structure.